Nearly three-fourths of life sciences organizations surveyed have invested in digital pathology to advance drug R&D, according to new research commissioned by Proscia. Over half of these organizations (53%) still center their operations around legacy software systems primarily for basic image viewing despite growing adoption of AI to accelerate the introduction of breakthrough therapeutics.
Featured Story:
Latest Articles
October 1, 2024